Childhood Infratentorial Ependymoma
14
0
0
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.1%
1 terminated out of 14 trials
92.3%
+5.8% vs benchmark
0%
0 trials in Phase 3/4
8%
1 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (14)
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Irinotecan in Treating Children With Refractory Solid Tumors
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma